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Abstract
Background: We studied the expression of DMBT1 (deleted in malignant brain tumor 1), a
putative tumor suppressor gene, in normal, proliferative, and malignant breast epithelium and its
possible relation to cell cycle.
Methods: Sections from 17 benign lesions and 55 carcinomas were immunostained with anti
DMBT1 antibody (DMBTh12) and sections from 36 samples, were double-stained also with anti
MCM5, one of the 6 pre-replicative complex proteins with cell proliferation-licensing functions.
DMBT1 gene expression at mRNA level was assessed by RT-PCR in frozen tissues samples from
39 patients.
Results: Normal glands and hyperplastic epithelium in benign lesions displayed a luminal polarized
DMBTh12 immunoreactivity. Normal and hyperplastic epithelium adjacent to carcinomas showed
a loss of polarization, with immunostaining present in basal and perinuclear cytoplasmic
compartments. DMBT1 protein expression was down-regulated in the cancerous lesions compared
to the normal and/or hyperplastic epithelium adjacent to carcinomas (3/55 positive carcinomas
versus 33/42 positive normal/hyperplastic epithelia; p = 0.0001). In 72% of cases RT-PCR confirmed
immunohistochemical results. Most of normal and hyperplastic mammary cells positive with
DMBTh12 were also MCM5-positive.
Conclusions: The redistribution and up-regulation of DMBT1 in normal and hyperplastic tissues
flanking malignant tumours and its down-regulation in carcinomas suggests a potential role in breast
cancer. Moreover, the concomitant expression of DMTB1 and MCM5 suggests its possible
association with the cell-cycle regulation.
Background
DMBT1 (Deleted in Malignant Brain Tumor) at chromo-
some 10q25.3–26.1, was considered a tumour suppressor
gene because frequent deletions and/or lack of expression
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the gastrointestinal tract [4,5], and the lung [6,7].
However, recent evidence has shown that DMBT1 is not a
typical tumour suppressor gene because it is up-regulated
in normal or inflamed epithelium adjacent to lung carci-
nomas as well as in some primary lung cancers and gliob-
lastomas [8]. It was also shown that mutations in
combination with loss of heterozygosity do not play a role
in DMBT1 inactivation in many tumours including breast
cancer [9,10]
DMBT1 is a multi-functional protein related to the Mac-2
binding protein and mucins that have a protective func-
tion and mediate cell-extracellular matrix interactions
[8,11]. DMBT1GP340(glycoprotein-340) and DMBT1SAG
(Salivary Agglutinin) are DMBT1 variants, present in the
respiratory tract and the oral cavity, respectively, that have
been linked to innate host defense and epithelial regener-
ation [3,12-16]. In the respiratory tract, DMBT1GP340is
involved in innate host defence by its interaction with the
lectins surfactant protein D and A (Sp-D, Sp-A) and by its
ability to stimulate alveolar macrophage migration
[12,13,17]. Another lectin, mannan binding protein
(MBP), has been shown to have an anti tumour effect
against gliomas and colorectal carcinomas in vitro and in
vivo [18,19]. While this anti tumor property remains to be
demonstrated for Sp-A and Sp-D, we have previously
reported the presence of surfactant protein A (Sp-A) in the
ductal epithelium of the normal breast and its variable
expression in mammary carcinomas. We found that in the
normal ductal epithelium Sp-A immunoreactivity is
present on the luminal side, whereas in carcinomas it is
present both on the luminal side as well as on the baso-
lateral surfaces. In carcinomas, the Sp-A immunoreactivity
is not only redistributed but also decreased as the histo-
logical tumour grade increases [20]. Remarkably, this
resembles the changes of DMBT1 expression and localisa-
tion observed in other tumor types originating from
mono-layered epithelia such as primary esophageal
adeno-carcinomas and lung carcinomas [5,8].
Hensin, the rabbit homologue of DMBT1, triggers epithe-
lial terminal differentiation by mediating cell-extracellu-
lar matrix (ECM) interactions, and this may apply also to
DMBT1 [3,21-24]. CRP-ductin, DMBT1 homologue in the
mouse, and a novel homologue in the rat (DMBT1 4,7
kb), have been linked to initiation of cell proliferation, dif-
ferentiation and repair [25,26]. It has been proposed that
translocation of DMBT1 to the ECM triggers cellular dif-
ferentiation, whereas a loss of expression of DMBT1
favours tumor cell growth [8].
These findings led us to explore whether similar principles
apply to breast epithelium. Here we examined the expres-
sion of DMBT1 in the morphologically normal, hyper-
plastic, and neoplastic breast epithelium. We also
examined in morphologically normal epithelium a possi-
ble association of DMBT1 expression with that of an early
proliferative marker such as MCM5 (Minichromosome
Maintenance protein 5). MCM5 is one of the 6 pre-repli-
cative complex proteins (MCM 2–7) [27] and its expres-
sion was compared with that of Ki 67 proliferation index.
Methods
Tissue and cell-lines
From the files of the Surgical Pathology at S.Paolo Univer-
sity Hospital, we retrieved paraffin blocks of 72 consecu-
tive breast lesions surgically resected. This material
included 16 cases of fibrocystic disease (FD), 1 case of
gynecomastia (GM), 10 samples of ductal carcinoma in
situ (DCIS) and 45 cases of infiltrating carcinoma (IC) (36
ductal, 2 lobular, 2 mixed lobular and ductal, 2 mucinous,
1 apocrine, 1 cribriform, 1 papillary).
RT-PCR (Reverse-Transcriptase Polymerase Chain Reac-
tion) was performed on 39 samples: i.e. 37 samples out of
the 55 carcinomas used for the immunohistochemical
studies, 1 sample of normal breast tissue that had been
removed with a neoplastic lesion and 1 sample of fibro-
cystic disease. All 39 samples had been quickly frozen in
liquid nitrogen after surgical resection and stored at -
80°C. As confirmed by histopathologic examination, in
all tumor specimens the amount of tumor cells equalled
or exceeded 80% of the overall sample. As controls for
each test a frozen sample of the same case positive with
immunohistochemical method was used. We also ana-
lysed by RT-PCR two breast cancer cell lines (Hs578T and
T-47D) obtained from the American Type Culture Collec-
tion and maintained as recommended.
Immunohistochemistry
Sections from blocks containing the predominant lesion
were incubated with anti DMBT1h12 monoclonal anti-
body [3] as well as anti Ki67 Mib1 (Dako Cytomation
DK). Double labelling with anti-DMBT1 and anti MCM5
monoclonal antibodies (Novocastra Laboratories Ltd,
Newcastle upon Tyne, U.K.) was performed on 17 benign
lesions and a subset of 19 in situ and invasive carcinomas
where residual normal breast tissue was well represented.
On these selected samples a single incubation with anti
MCM5 and anti Ki 67 antibody was performed in order to
compare the two respective immunoreactivities. Antibod-
ies were diluted as follows: anti-DMBT1h12, 1:500; anti
MCM5, 1:40; anti Ki 67 Mib1, 1:100. For anti-DMBT1 and
Ki 67 Abs, sections were pre-treated for antigen retrieval in
boiling 0.01 M sodium citrate buffer pH 6, in microwave
(MW) oven for 12 minutes. DMBT1 and MCM5 double
labelling was performed in two steps following a modifi-
cation of the method of Lan et al. [28], briefly: 1) firstPage 2 of 9
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oven three times, followed by 1 h incubation with anti
DMBT1h12. The reaction was developed with alkaline
phosphatase using Fucsin + (Dako) as chromogen. 2)
same antigen retrieval followed by over-night incubation
with anti MCM5 Ab and development with peroxydase
and diaminobenzidine (DAB) as chromogen. All slides
were incubated in an automated slides stainer (Biogenex,
S.Ramon, CA, U.S.A.); reaction products were visualized
by En Vision product (Dako). Negative and positive con-
trols were added in each experiment.
Three investigators (AM, PB, PGN) evaluated separately
DMBTh12 immunopositivity of morphologically normal,
hyperplastic, and malignant cells. Immunopositivity was
scored in 4 distinct categories according to the percentage
of positive cells: 0 = negative, 1 = < 10%, 2 = 10%–50%
and 3 = > 50%. MCM5 and Ki67 positivity in morpholog-
ically normal epithelium was determined with a semi-
quantitative method: percentage of positive glandular
structure and number of positive cells observed in each
positive gland divided number of glands.
RNA extraction
Total RNA was extracted from breast specimens using Tri-
zol reagent, (Invitrogen s.r.l., S. Giuliano Milanese, Italy)
according to the manufacturer's instructions. Total RNA
was quantified and checked for purity by UV
spectrophotometry.
cDNA synthesis
Reverse transcription of RNA was done in a final volume
of 20 µl containing 1x buffer (50 mM KCl, 15 mM Tris-
HCl, pH 8.3), 500 µM each deoxynucleotide triphos-
phate, 5 mM MgCl2, 20 units of RNase inhibitor, 50 units
of MuLV Reverse Transcriptase, 2.5 µM Random hexamers
and 1 µg of total RNA. All reagents were purchased by the
supplayer (Applied Biosystems, Foster City, CA, USA). The
samples were incubated at 25°C for 10 min, 42°C for 60
min and at 95°C for 5 min.
PCR amplification
Polymerase chain reaction (PCR) of the cDNA was per-
formed in a final volume of 50 µl containing all four
dNTPs (each at 200 µM), 1X buffer, 1.5 mM MgCl2, 1.25
units of Taq Gold DNA polymerase and each primer at 0.3
µM. The PCR amplification of DMBT1 was carried out in
two steps, following a nested procedure. In the first step
we used 2 µl of cDNA from the reverse transcription and
in the second 2 µl of the first PCR product as template.
Primers and thermal condition were used according to
Mollenhauer et al [3]. The specificity of the PCR product
was confirmed by sequencing with BigDyeTM terminator
chemistry using the genetic analyser ABI Prism 310
(Applied Biosystems), β-2-microglobulin (as control for
sample integrity) was amplified in the amplification mix-
ture described above and using the following primers: 5'-
TCTGGGTTTCATCCATCCGA-3' and 5'-CCCCAAAT-
TCTAAGCAGAGTATGTAA-3'. The thermal cycling param-
eters were: initial step of 10 min at 94°C, 39 cycles at
94°C for 30 sec, 58°C for 30 sec, 72 °C for 30 sec, and a
final step for 5 min at 72°C. All the PCR products were
separated by electrophoresis on a 1.5% agarose gel con-
taining ethidium bromide and visualized under UV tran-
sillumination. Amplification product of 602 bp (β-2-
microglobulin) and 435 bp (DMBT1) were obtained.
Data analysis
Statistical differences between immunopositive cases/
total number of cases were calculated by Fisher's exact test.
p value less than 0.05 were considered statistically
significant.
T-test for independent values was used to evaluate statisti-
cally significant differences between immunoreactivity of
normal and hyperplastic epithelium in benign, pre-inva-
sive and invasive lesions.
Results
Immunohistochemistry
Different patterns of immunopositivity were observed in
the histologically normal and hyperplastic breast tissue,
present in the sections of benign and malignant lesions: a)
single supra-nuclear, intra-cytoplasmic dot polarized
toward luminal surface [Figure 1a]; b) a strong surface
decoration of luminal cells [Figure 1b], c) intra-luminal
immuno-reactive material [Figure 1c], d) multiple, ran-
domly distributed peri-nuclear, irregular dots [Figure 1d],
e) marked supra-nuclear and/or baso-lateral accumula-
tion of reaction product [Figure 1e] and f) strong diffuse
granular intra-cytoplasmic decoration [Figure 1f]. Mor-
phologically normal ducts showed the pattern of immu-
nopositivity described in section a). In addition to pattern
a), the epithelium in benign lesions showed immunoreac-
tivity patterns b) and c). Hyperplastic tissues flanking car-
cinoma frequently showed depolarization of immuno-
reaction of patterns d), e), and f).
Normal and hyperplastic mammary structures displayed a
variable DMBTh12 immunoreactivity: some ducts were
decorated while others were negative. Moreover a variable
percentage of cells was immunopositive. This heterogene-
ity suggests that there is no constitutive expression of
DMBT1 at protein level in the mammary gland epithe-
lium. In tumour areas, only 3 out of 55 carcinomas
showed variable degrees of immunopositivity with anti-
DMBTh12 Ab: in one case there was a widespread and
strong decoration of numerous tumour cells (immunopo-
sitivity score = 3) with irregularly distributed dots [Figure
1g]; in the second case only few cells had cytoplasmicPage 3 of 9
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BMC Cancer 2004, 4:46 http://www.biomedcentral.com/1471-2407/4/46Immunoreactivity of mammary epithelium with anti DMBTh12 AbFigure 1
Immunoreactivity of mammary epithelium with anti DMBTh12 Ab: a, supranuclear dot positivity in morphologically normal 
breast sample; b, strong, abundant surface immunoreactivity in a case of fibrocystic disease; c, intraluminal immunoreactive 
material in a case of gynecomastia; d, numerous supranuclear and randomly distributed positive dots in intraductal papillomato-
sis near an infiltrating ductal carcinoma; e, strong supranuclear and baso-lateral cytoplasmic immunoreactivity of hyperplastic 
ductal cells in a case of mucinous infiltrating carcinoma; f, granular diffuse intracytoplasmic positivity of hyperplastic intraductal 
cells in a case of carcinoma in situ; g, numerous positive malignant tumour cells of an infiltrating ductal carcinoma; h, few posi-
tive cells in an infiltrating ductal carcinoma; i, completely negative neoplastic cells of an invasive carcinoma; the arrow points to 
positive cells with large elongate nuclei in a non neoplastic duct facing normal negative cells.Page 4 of 9
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the third case only weak granular decoration in a small
clusters of cells was present (immunopositivity score = 1).
All other carcinomas were completely negative (immuno-
positivity score = 0) [Figure 1i]. Down-regulation of
DMBT1 expression in the cancerous lesions compared to
the normal and/or hyperplastic epithelium was statisti-
cally significant for both, ductal carcinoma in situ (DCIS)
(1/10 versus 33/42 normal and/or hyperplastic epithelia;
p = 0.0001) and invasive carcinoma (IC) (2/45 versus 33/
42 normal and/or hyperplastic epithelia; p < 0.0001).
The results of DMBT1 expression at protein and mRNA
level are summarized in table 1.
According to the 4 category scoring system, there was no
statistically significant difference of DMBT1 immunoreac-
tive cells between the normal and the hyperplastic epithe-
lium that flanked benign lesions, in situ and invasive
carcinomas (Table 2).
Double immunostaining with DMBTh12 Ab and anti
MCM5 Ab revealed a co-expression of the two antigens,
respectively, in the cytoplasm and the nucleus of the same
cells in morphologically normal breast epithelium (Figure
2a,2b). Conversely, glands that were negative with anti
DMBT1 were negative also with anti MCM5 antibody
(Figure 2b). DMBT1 and MCM5 positive or negative
glands were morphologically undistinguishable. In com-
parison to MCM5, very few morphologically normal epi-
thelial cells labelled by Anti DMBT1 Ab, expressed Ki67
(Figure 3a,3b,3c). 30–50% of glands were positive with
anti MCM5 Ab with a mean number of 4,5 positive cells
per positive glandular structure versus less than 10% of
positive glands with a mean number of 1,46 positive cell
per positive glandular structure with anti Ki 67 Ab. As
expected for a pre-replicative marker, anti MCM5 Ab dec-
orated diffusely all benign proliferative and malignant
lesions. The percentage of Ki 67 positive cells of carcino-
mas varied and was assessed as part of the protocol for the
surgical pathology diagnosis of breast neoplasia together
with other prognostic parameters i.e. hormonal receptors
status and Her2 Neu positivity. These data did not corre-
late with DMBT1 expression.
Expression analysis by RT-PCR
In 28/39 cases (72%) RT-PCR confirmed immunohisto-
chemical results, whereas 11 tumours that were negative
with anti-DMBTh12 revealed PCR-products after RT-PCR
amplification (Table 1). In two of these discordant cases
we could document the presence in the sample of residual
normal epithelial cells. DMBT1 mRNA was detected in
both the breast carcinoma cell lines analysed: Hs 578T
(Figure 4) and T47D (not shown).
Table 1: Immunohistochemical and RT-PCR expression of DMBT1 in benign and malignant mammary epithelium as number of positive 
cases/total number of cases. We considered positive the cases in which we found any percentage of positive cells.
FD/GM Normal/Hyperplastic DCIS IC
IHC 15/17 (88%) 33/42 (78%) 1/10 (10%) 2/45 (4%)
RT-PCR 1/1 1/1 0/2 13/35 (37%)
IHC= immunohistochemestry FD/GM = fibrocystic disease and gynecomastia Normal/Hyperplastic = morphologically normal and/or hyperplastic 
tissues flanking carcinoma DCIS = ductal carcinoma in situ IC = invasive carcinoma
Table 2: DMBTh12 staining scores in normal (N) and hyperplastic epithelium (H) flanking fibrocystic disease and gynecomastia (FD/
GM), ductal carcinoma in situ (DCIS) and invasive carcinoma (IC)
Immunohistochemical 
postivity score
Epithelium type FD/GM cases/total 
number*
DCIS cases/total number* IC cases/total number*
0 N 4/14 0/8 11/37
H 3/14 0/4 16/22
1 N 0/14 6/8 16/37
H 1/14 1/4 10/22
2 N 8/14 1/8 9/37
H 8/14 2/4 4/22
3 N 2/14 1/8 1/37
H 2/14 1/4 2/22
* total number of cases in which was present normal or hyperplastic epithelium.Page 5 of 9
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histological parameters or with IHC expression of hormo-
nal receptors, proliferation index Ki 67 and Her 2/Neu.
Discussion
In the present study we investigated DMBT1 expression by
immunohistochemistry and RT-PCR in benign and malig-
nant breast epithelial lesions. By immunohistochemistry
we found a variable DMBTh12 positivity in the morpho-
logically normal and hyperplastic epithelium adjacent to
benign (88%) and malignant (78%) lesions. Among 55
carcinomas we could detect immunopositivity only in 3
tumours (5%); in one case of infiltrating carcinoma the
immunopositivity was widespread with a pattern similar
to that seen in hyperplastic lesions near carcinoma; in the
other two cases (one carcinoma in situ and one infiltrating
a, double staining of morphologically normal mammary epithelium: with anti DMBTh12 Ab (red stain in the cytoplasm) and with anti MCM5 Ab (Brown sta n in the nucleus)Figure 2
a, double staining of morphologically normal mammary epithelium: with anti DMBTh12 Ab (red stain in the cytoplasm) and 
with anti MCM5 Ab (Brown stain in the nucleus); b, lower magnification of double labelled mammary tissue; arrow points to a 
structure negative for both antigens.
Immuno-reactivity of normal mammary epithelium in three serial sections incubated with: a, anti DMBTh12 AbFigure 3
Immuno-reactivity of normal mammary epithelium in three serial sections incubated with: a, anti DMBTh12 Ab; b, anti MCM5 
Ab and c, anti Ki 67 antibody where only few cells are labelled. Inset: higher magnification of the same ductal structure.
D bPage 6 of 9
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DMBT1 expression was detected by RT-PCR in 13 of 35
(37%) infiltrating carcinomas and in 2 breast cancer cell
lines. Eleven tumours, that were negative with anti-
DMBTh12, revealed PCR-products after RT-PCR amplifi-
cation. This discordance between IHC and RT-PCR results
may be due to residual normal epithelial cells present in
the sample. Furthermore other possible reasons of this
discrepancy could be: 1) the greater sensitivity of molecu-
lar technique like RT-PCR in detecting very low expression
levels of DMBT1 that were below detection by immuno-
histochemistry, 2) sampling problems i.e. the presence of
few positive tumour cells only in the frozen samples or 3)
few immunoreactive cells have been missed by micro-
scopic examination and finally 4) DMBT1 protein could
have an altered epitope not recognized by its paratope in
the antibody. By either immunohistochemistry or
molecular technique we found no correlation between
DMBT1 expression and tumor histotype, grade, hormonal
receptors status, proliferation index, Her2 Neu expression
or lymph-nodal metastases.
In a recent paper on breast carcinogenesis, qualitatively
similar data were reported for DMBT1 in human breast
cancer, but an indirect weak correlation between the
degree of differentiation of the breast carcinomas and the
extent of the immunoreactivity was found [10]. The dis-
crepancy in the results between our and this study may be
due to sampling problems, the size of the sample and het-
erogeneous expression of DMBT1 in breast cancer or to
other poorly-defined factors such as race, age or hormonal
status of the population under study. Mollenhauer et al.
point out that DMBT1 expression may be up-regulated in
pathophysiological conditions such as inflammation,
liver injury or after carcinogen administration and it is
down-regulated in tumors to achieve a growth advantage
in a dynamic and complex model. Also according to these
authors, the possibility that DMBT1 loss may be a conse-
quence rather than a primary event in carcinogenesis is
unlikely (10).
Although the normal mammary gland has been reported
to have low DMBT1 expression by RT-PCR [12], we found
variable DMBTh12 immunopositivity in breast epithe-
lium flanking benign and malignant lesions. Immunopo-
sitive epithelial cells in our material appeared either
morphologically normal and indistinguishable from
immunonegative cells or hypertrophic with abundant
cytoplasm and large elongated nuclei oriented perpendic-
ularly to the basement membrane [Figure 1i]. Moreover,
DMBTh12 immunoreactivity was also maintained in
hyperplastic epithelium flanking carcinomas. This resem-
bles the DMBT1 expression patterns observed in the
human respiratory tract and in associated inflammation
and carcinomas [8] and suggest that the variable DMBT1
expression in the normal mammary gland epithelium
may result from the necessity of DMBT1 induction.
Indeed, in parallel in vivo studies, it was found that
DMBT1 is strongly up-regulated in the mammary gland
tissue of the mouse shortly after carcinogen-administra-
tion and prior to the onset of histo-pathologically visible
symptoms [10]. It has been reported that Sp-D and Sp-A
are ligands of DMBT1 products [29]. We recently demon-
strated that Sp-A, in breast carcinoma tissues, has a pattern
DMBT1 expression assessed by RT-PCRFigure 4
DMBT1 expression assessed by RT-PCR. Both DMBT1 (435 bp) and β-2microglobulin (602 bp) products were loaded in the 
same well. Lane M: size marker (50 bp ladder), lane 1: cell line Hs 578T, lanes 2, 3, 4, 5: breast carcinomas, lane 6: negative con-
trol without template.
650 bp
600 bp
450 bp
400 bp
M 1 2 3 4 5 6Page 7 of 9
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[20]; thus, we hypothesize that co-ordinated induction of
both SP-A and DMBT1 in breast tissue may be part of a
protective response as suggested by Kang et al [30] for
DMBT1 and Sp-D in pulmonary epithelium.
While this interaction may be attributed to lumenally
secreted DMBT1, the depolarisation of the staining
patterns indicates that DMBT1 may also be secreted to
other destinations, i.e. the ECM, by the mammary gland
epithelial cells. In this regard, the second putative func-
tion of DMBT1, i.e. triggering of epithelial differentiation,
is noteworthy. It may prevent hyperproliferative epithelial
cells from out-of control proliferation and progression to
the tumor state. This view is supported by two present
findings. The correlation between MCM5 and DMBT1
expression may point to a coupling to cell-cycle processes:
basolateral relocation and hyper-expression of DMBT1 at
the ECM may provide cells that are licensed to proliferate
with protection from unregulated proliferation. On the
other hand loss of DMBT1 expression in a significant
numbers of DCISs and ICs is consistent with the notion
that DMBT1 inactivation may offer growth advantages to
neoplastic cells [10]. The loss of DMBT1 expression
appears to take place early, i.e. already at the time of tran-
sition from hyperplastic lesions to carcinoma, as it has
been reported in oesophageal squamous cell carcinomas
[5].
The exact mechanisms for DMBT1 inactivation remain
unclear. An inactivation by mutation appears not to be a
major mechanism for DMBT1 inactivation in tumors
[10,31] The studies of Munoz and co-workers suggest that
epigenetic silencing of either DMBT1 or genes that regu-
late DMBT1 expression takes place in some tumors [32].
Accordingly, except for direct epigenetic silencing of the
DMBT1 promotor, loss of expression or mutation of
DMBT1-regulatory genes might represent alternative can-
didate mechanisms.
Conclusions
We have shown that DMBT1 expression and cellular loca-
tion in breast epithelium varies in normal, hyperplastic
and neoplastic cells. In normal or hyperplastic tissue
flanking carcinomas it is up-regulated and polarized
toward glandular lumen or the basolateral membrane
while it is down-regulated in carcinomas. These findings
closely resemble the patterns observed for its interaction
partner SP-A in an earlier study. Additionally we have
shown that DMBT1 is co-expressed with MCM5 in normal
and hyperplastic tissue. We hypothesize that hyper-
expression and basolateral relocation of DMBT1 in these
epithelia prevents the out of control growth that charac-
terizes neoplastic epithelium.
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